{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T06:01:42Z","timestamp":1787032902507,"version":"build-2736575974"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,5]]},"DOI":"10.7759\/cureus.83513","type":"journal-article","created":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T10:26:41Z","timestamp":1746440801000},"source":"Crossref","is-referenced-by-count":4,"title":["Vitiligo-Like Depigmentation Induced by Cyclin-Dependent Kinase 4\/6 Inhibitors in the Treatment of Metastatic Breast Cancer: A Case Report and Literature Review"],"prefix":"10.7759","author":[{"given":"Chuan Yaw","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia","family":"Tang-Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sok Yuen","family":"Beh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2114663","article-title":"Overall survival with ribociclib plus letrozole in advanced breast cancer","volume":"386","author":"Hortobagyi GN","year":"2022","unstructured":"Hortobagyi GN, Stemmer SM, Burris HA, et al.. Overall survival with ribociclib plus letrozole in advanced breast cancer. N Engl J Med. 2022, 386:942-50. 10.1056\/NEJMoa2114663","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2023.41.17_suppl.lba500","article-title":"Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+\/HER2- early breast cancer: Primary results from the phase III NATALEE trial","volume":"41","author":"Slamon D","year":"2023","unstructured":"Slamon D, Stroyakovskiy D, Yardley D, et al.. Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+\/HER2- early breast cancer: Primary results from the phase III NATALEE trial. J Clin Oncol. 2023, 41:10.1200\/jco.2023.41.17_suppl.lba500","journal-title":"J Clin Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S344867","article-title":"Vitiligo-like lesions in a patient with metastatic breast cancer treated with cyclin-dependent kinase (CDK) 4\/6 inhibitor: a case report and literature review","volume":"15","author":"Sharaf B","year":"2022","unstructured":"Sharaf B, AlMasri R, Abdel-Razeq N, Salama O, Hamad I, Abunasser M, Abdel-Razeq H. Vitiligo-like lesions in a patient with metastatic breast cancer treated with cyclin-dependent kinase (CDK) 4\/6 inhibitor: a case report and literature review. Clin Cosmet Investig Dermatol. 2022, 15:5-10. 10.2147\/CCID.S344867","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1177\/10781552231156521","article-title":"Vitiligo-like lesions associated with ribociclib in a woman with metastatic breast cancer","author":"T\u00fcrkel A","year":"2023","unstructured":"T\u00fcrkel A, Kara\u00e7in C, \u00d6ner \u0130, \u015eeyran E, \u00d6ks\u00fczo\u011flu B. Vitiligo-like lesions associated with ribociclib in a woman with metastatic breast cancer. J Oncol Pharm Pract. 2023, 10781552231156521. 10.1177\/10781552231156521","journal-title":"J Oncol Pharm Pract"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30292-4","article-title":"Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial","volume":"7","author":"Tripathy D","year":"2018","unstructured":"Tripathy D, Im S, Colleoni M, et al.. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018, 7:904-15. 10.1016\/S1470-2045(18)30292-4","journal-title":"Lancet Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-020-05914-w","article-title":"Vitiligo-like lesions in patients with advanced breast cancer treated with cycline-dependent kinases 4 and 6 inhibitors","volume":"185","author":"Sollena P","year":"2021","unstructured":"Sollena P, Nikolaou V, Soupos N, et al.. Vitiligo-like lesions in patients with advanced breast cancer treated with cycline-dependent kinases 4 and 6 inhibitors. Breast Cancer Res Treat. 2021, 185:247-53. 10.1007\/s10549-020-05914-w","journal-title":"Breast Cancer Res Treat"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-024-03431-x","article-title":"The efficacy and safety of dalpiciclib, a cyclin-dependent kinase 4\/6 inhibitor, in patients with advanced head and neck mucosal melanoma harboring CDK4 amplification","volume":"22","author":"Shi C","year":"2024","unstructured":"Shi C, Ju H, Zhou R, et al.. The efficacy and safety of dalpiciclib, a cyclin-dependent kinase 4\/6 inhibitor, in patients with advanced head and neck mucosal melanoma harboring CDK4 amplification. BMC Med. 2024, 22:215. 10.1186\/s12916-024-03431-x","journal-title":"BMC Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.4103\/ijp.ijp_85_23","article-title":"Photoallergic dermatitis and vitiligo-like lesion in a patient with metastatic breast cancer using ribociclib","volume":"55","author":"Mente\u015fo\u011flu D","year":"2023","unstructured":"Mente\u015fo\u011flu D. Photoallergic dermatitis and vitiligo-like lesion in a patient with metastatic breast cancer using ribociclib. Indian J Pharmacol. 2023, 55:190-1. 10.4103\/ijp.ijp_85_23","journal-title":"Indian J Pharmacol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2022-248782","article-title":"Ribociclib-induced extensive vitiligo-like lesions: possible pathomechanisms with clinical, dermoscopic and histological correlation","volume":"15","author":"Anjaneyan G","year":"2022","unstructured":"Anjaneyan G, Keechilat P, Duraisamy P, Eapen M. Ribociclib-induced extensive vitiligo-like lesions: possible pathomechanisms with clinical, dermoscopic and histological correlation. BMJ Case Rep. 2022, 15:10.1136\/bcr-2022-248782","journal-title":"BMJ Case Rep"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-148X.2010.00820.x","article-title":"Advances in melanoma senescence and potential clinical application","volume":"24","author":"Giuliano S","year":"2011","unstructured":"Giuliano S, Ohanna M, Ballotti R, Bertolotto C. Advances in melanoma senescence and potential clinical application. Pigment Cell Melanoma Res. 2011, 24:295-308. 10.1111\/j.1755-148X.2010.00820.x","journal-title":"Pigment Cell Melanoma Res"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2019.00023","article-title":"Immunomodulatory roles of cell cycle regulators","volume":"7","author":"Laphanuwat P","year":"2019","unstructured":"Laphanuwat P, Jirawatnotai S. Immunomodulatory roles of cell cycle regulators. Front Cell Dev Biol. 2019, 7:23. 10.3389\/fcell.2019.00023","journal-title":"Front Cell Dev Biol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.25259\/IJDVL_239_2024","article-title":"Ribociclib induced vitiligo-like lesions","volume":"91","author":"Kothari R","year":"2025","unstructured":"Kothari R, Darling HS, Bhatnagar A, Janney M, Mohan S, Kumar R. Ribociclib induced vitiligo-like lesions. Indian J Dermatol Venereol Leprol. 2025, 91:396-7. 10.25259\/IJDVL_239_2024","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.13585","article-title":"Drug induced vitiligo-like depigmentation from a CDK 4\/6 inhibitor","volume":"18","author":"Chan OB","year":"2022","unstructured":"Chan OB, Su JC, Yazdabadi A, Chan A. Drug induced vitiligo-like depigmentation from a CDK 4\/6 inhibitor. Asia Pac J Clin Oncol. 2022, 18:e154-6. 10.1111\/ajco.13585","journal-title":"Asia Pac J Clin Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1067264","article-title":"Case report: vitiligo-like toxicity due to ribociclib during first-line treatment of metastatic breast cancer: two cases of premature interruption of therapy and exceptional response","volume":"13","author":"Pasqualoni M","year":"2023","unstructured":"Pasqualoni M, Orlandi A, Palazzo A, et al.. Case report: vitiligo-like toxicity due to ribociclib during first-line treatment of metastatic breast cancer: two cases of premature interruption of therapy and exceptional response. Front Oncol. 2023, 13:1067264. 10.3389\/fonc.2023.1067264","journal-title":"Front Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/phpp.12923","article-title":"Vitiligo-like depigmentation affecting sun-exposed areas caused by palbociclib","volume":"40","author":"P\u00e9rez NB","year":"2024","unstructured":"P\u00e9rez NB, Mill\u00e1n PI, Men\u00e9ndez AD, Dom\u00ednguez Au\u00f1\u00f3n JD. Vitiligo-like depigmentation affecting sun-exposed areas caused by palbociclib. Photodermatol Photoimmunol Photomed. 2024, 40:e12923. 10.1111\/phpp.12923","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-023-07217-2","article-title":"Multi-center retrospective review of vitiligo-like lesions in breast cancer patients treated with cyclin-dependent kinase 4 and 6 inhibitors","volume":"204","author":"Bang AS","year":"2024","unstructured":"Bang AS, Fay CJ, LeBoeuf NR, et al.. Multi-center retrospective review of vitiligo-like lesions in breast cancer patients treated with cyclin-dependent kinase 4 and 6 inhibitors. Breast Cancer Res Treat. 2024, 204:643-7. 10.1007\/s10549-023-07217-2","journal-title":"Breast Cancer Res Treat"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.62293","article-title":"Palbociclib-induced vitiligo-like lesions: a report of a challenging case","volume":"16","author":"Algethami AK","year":"2024","unstructured":"Algethami AK, Alshareef AM, Alhawsawi WK, et al.. Palbociclib-induced vitiligo-like lesions: a report of a challenging case. Cureus. 2024, 16:e62293. 10.7759\/cureus.62293","journal-title":"Cureus"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3389\/pore.2023.1611115","article-title":"Vitiligo-like lesions induced by cyclin-dependent kinase 4\/6 inhibitor palbociclib: a case report and literature review","volume":"29","author":"Gao S","year":"2023","unstructured":"Gao S, Wei G, Hao Y. Vitiligo-like lesions induced by cyclin-dependent kinase 4\/6 inhibitor palbociclib: a case report and literature review. Pathol Oncol Res. 2023, 29:1611115. 10.3389\/pore.2023.1611115","journal-title":"Pathol Oncol Res"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.16356","article-title":"Vitiligo-like lesions induced by cyclin-dependent kinase 4\/6 inhibitor palbociclib","volume":"62","author":"Romagnuolo M","year":"2023","unstructured":"Romagnuolo M, Alberti Violetti S, Riva D, Barberi F, Moltrasio C. Vitiligo-like lesions induced by cyclin-dependent kinase 4\/6 inhibitor palbociclib. Int J Dermatol. 2023, 62:e98-e100. 10.1111\/ijd.16356","journal-title":"Int J Dermatol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.5826\/dpc.1202a45","article-title":"Ribociclib-induced vitiligo: a case report","volume":"12","author":"Silvestre Torner N","year":"2022","unstructured":"Silvestre Torner N, Aguilar Mart\u00ednez A, Echarri Gonz\u00e1lez MJ, Tabbara Carrascosa S, Rom\u00e1n Sainz J, Gruber Velasco F. Ribociclib-induced vitiligo: a case report. Dermatol Pract Concept. 2022, 12:e2022045. 10.5826\/dpc.1202a45","journal-title":"Dermatol Pract Concept"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/358332-vitiligo-like-depigmentation-induced-by-cyclin-dependent-kinase-46-inhibitors-in-the-treatment-of-metastatic-breast-cancer-a-case-report-and-literature-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T10:26:41Z","timestamp":1746440801000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/358332-vitiligo-like-depigmentation-induced-by-cyclin-dependent-kinase-46-inhibitors-in-the-treatment-of-metastatic-breast-cancer-a-case-report-and-literature-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,5]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.83513","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,5]]}}}